Compare Abeona Therapeutics Inc (ABEO) vs Huntington Ingalls Industries Inc (HII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Huntington Ingalls Industries Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Huntington Ingalls Industries Inc trades at $328.09 (market cap $12.92B). The key difference: Huntington Ingalls Industries Inc is far larger — about 30.7× Abeona Therapeutics Inc's market cap, and Huntington Ingalls Industries Inc pays a 1.68% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HII | |
|---|---|---|
Market Cap | $421.19M | $12.92B |
Sector | Health | Technology |
52-Week High | $7.45 | $453.73 |
52-Week Low | $4.17 | $265.40 |
Enterprise Value | $276.10M | $15.84B |
Dividend Yield | — | 1.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
HII trades at $324.38, down 1.94% on the day, with a bullish technical signal supported by moving averages and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $5.27, exceeding expectations, and secured a $2.2 billion contract for surveillance capabilities (GlobeNewsWire, August 11, 2026). Valuation ratios include a P/E of 19.53 and P/S of 0.98, indicating reasonable pricing relative to earnings and sales.
Outlook remains positive due to contract wins and margin expansion, but risks include dependence on U.S. defense spending and competitive pressures. The consensus price target of $359.67 suggests upside potential, supported by 44% buy ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →
